Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. [electronic resource]
Producer: 20090616Description: 1091-7 p. digitalISSN:- 1524-4563
- Administration, Oral
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
- Antihypertensive Agents -- administration & dosage
- Blood Pressure Monitoring, Ambulatory
- Cyclic Nucleotide Phosphodiesterases, Type 5 -- administration & dosage
- Delayed-Action Preparations -- administration & dosage
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Hypertension -- diagnosis
- Male
- Middle Aged
- Multivariate Analysis
- Pharmaceutical Preparations
- Phosphodiesterase 5 Inhibitors
- Reference Values
- Risk Assessment
- Severity of Illness Index
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.